Brian Savage - 11 Feb 2026 Form 3 Insider Report for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

Role
Interim Chief Legal Officer
Signature
/s/ Dov Bergwerk as attorney-in-fact for Brian P. Savage
Issuer symbol
TEVA
Transactions as of
11 Feb 2026
Net transactions value
$0
Form type
3
Filing time
23 Feb 2026, 16:17:10 UTC
Next filing
05 Mar 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Savage Brian Interim Chief Legal Officer C/O TEVA PHARMACEUTICAL INDUSTRIES LTD., 124 DVORA HANEVI'A STREET, TEL AVIV, ISRAEL /s/ Dov Bergwerk as attorney-in-fact for Brian P. Savage 23 Feb 2026 0002112339

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding TEVA Ordinary Shares 739 11 Feb 2026 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding TEVA Stock Options (right to buy) 11 Feb 2026 Ordinary Shares 2,253 $53.50 Direct F1, F2
holding TEVA Stock Options (right to buy) 11 Feb 2026 Ordinary Shares 4,503 $34.70 Direct F1, F3
holding TEVA Restricted Share Units 11 Feb 2026 Ordinary Shares 18,967 Direct F1, F4, F5
holding TEVA Restricted Share Units 11 Feb 2026 Ordinary Shares 13,844 Direct F1, F5, F6
holding TEVA Restricted Share Units 11 Feb 2026 Ordinary Shares 15,066 Direct F1, F5, F7
holding TEVA Restricted Share Units 11 Feb 2026 Ordinary Shares 14,320 Direct F1, F5, F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2 Stock options were granted on March 17, 2016, with 563 vested on each of March 17, 2017, March 17, 2018 and March 17, 2019, and 564 vested on March 17, 2020.
F3 Stock options were granted on March 3, 2017, with 1,125 vested on each of March 3, 2018, March 3, 2019 and March 3, 2020, and 1,128 vested on March 3, 2021.
F4 Restricted share units were granted on March 4, 2022, with 4,741 vested on each of March 4, 2023, March 4, 2024 and March 4, 2025, and 4,744 vesting on March 4, 2026.
F5 Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
F6 Restricted share units were granted on March 3, 2023, with 3,461 vested on each of March 3, 2024 and March 3, 2025, and 3,461 vesting on each of March 3, 2026 and March 3, 2027.
F7 Restricted share units were granted on March 4, 2024, with 3,766 vested on March 4, 2025, 3,766 vesting on each of March 4, 2026 and March 4, 2027, and 3,768 vesting on March 4, 2028.
F8 Restricted share units were granted on March 5, 2025, with 3,580 vesting on each of March 5, 2026, March 5, 2027, March 5, 2028 and March 5, 2029.